Stay informed with the latest industry insights from Tufts CSDD. Explore our collection of press releases, addressing critical topics and emerging trends that shape the future of drug development and innovation.
January 2025
How a ‘Rising Tide’ of Inclusivity is Transforming Clinical Trials | Drug Discovery and Development
Description: A growing focus on inclusivity is reshaping clinical trials, ensuring diverse representation and better outcomes for all populations. Explore the strategies, challenges, and groundbreaking shifts that are making clinical research more equitable and impactful. Read more at: https://www.drugdiscoverytrends.com/how-a-rising-tide-of-inclusivity-is-transforming-clinical-trials/
The Clinical Trials of 2025 | The Medicine Maker
Description: What will clinical trials look like in the near future? This forward-looking article explores cutting-edge innovations, regulatory shifts, and transformative trends that are set to redefine the clinical trial landscape by 2025. From AI-driven insights to patient-centric models, discover what’s shaping the next era of medical research: https://themedicinemaker.com/business-regulation/the-clinical-trials-of-2025
October 2024
How to Measure ROI in Decentralized Clinical Trials | Clinical Trial Vanguard
Description: How can you effectively measure the return on investment in decentralized clinical trials? This article dives into key metrics, strategies, and insights shared by industry experts to assess the financial and operational impact of decentralized trial models. Learn how to balance innovation with cost-effectiveness and optimize your trial outcomes: https://www.clinicaltrialvanguard.com/conference-coverage/how-to-measure-roi-in-decentralized-clinical-trials/
DPHARM 2024 Highlights ClinOps Innovations That Address Cost, Complexity, & Capabilities | Clinical Leader
This colulmn highlights groundbreaking insights from the DPHARM conference, showcasing clinical operations innovations designed to address the rising cost, complexity, and capability challenges in modern trials. Discover how cutting-edge solutions are streamlining processes, enhancing efficiency, and driving impactful change in clinical research: https://www.clinicalleader.com/doc/dpharm-highlights-clinops-innovations-that-address-cost-complexity-capabilities-0001
September 2024
Examining Short and Long-Term ROI of DCT Deployments | Applied Clinical Trials
Description: Ken Getz, Executive Director and Research Professor, shares insights on DCT deployments at the DPharm 2024 conference. Nicholas Saraceno, ACT Editor, summarizes Ken’s presentation on the ROI of DCT deployments, organizational techniques for clinical trial planning and execution, and insights from the PACT Consortium. Access the full article here: https://www.appliedclinicaltrialsonline.com/view/analyzing-dct-deployments
The Relationship Between Participant Diversity and DCT Use in Clinical Trials | Applied Clinical Trials
Description: Tufts CSDD Executive Director Ken Getz delves into the crucial connection between participant diversity and decentralized clinical trials (DCTs). He explores how DCTs can break down barriers to participation, ensuring that clinical research better represents diverse populations. With a growing push for inclusivity in healthcare, this piece highlights the potential of DCTs to drive more equitable, accessible, and generalizable clinical trial outcomes. Access the full article here: https://www.appliedclinicaltrialsonline.com/view/relationship-between-participant-diversity-and-dct-in-clinical-trials
Description: FDA issued a draft guidance as part of the agency’s efforts to advance innovations in clinical trial design and conduct which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols and procedures that focus on essential data collection, allowing integration of research into routine clinical practice. This may improve convenience and accessibility for participants and allow for enrollment of more representative populations, resulting in more generalizable trial results. Learn more about the FDA Guidance here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/integrating-randomized-controlled-trials-drug-and-biological-products-routine-clinical-practice
July 2024
Decentralized Clinical Trials: A New Era of Diversity | Clinical Trial Vanguard
Description: This article explores how decentralized clinical trials are revolutionizing the healthcare industry by breaking barriers to participation and fostering greater inclusivity. Learn from industry leaders as they discuss the challenges, innovations, and transformative potential of this approach in creating a more diverse and representative clinical trial landscape. Learn more here: https://www.clinicaltrialvanguard.com/executiveinterviews/decentralized-clinical-trials-a-new-era-of-diversity/
June 2024
A recent study by the Partnership for Advancing Clinical Trials (PACT) reveals that decentralized clinical trials (DCTs) often surpass traditional trials in meeting timeline expectations. The findings shed light on how DCTs are influencing the pace and efficiency of clinical research. Read the press release: https://www.businesswire.com/news/home/20240611375126/en/New-Research-from-Partnership-for-Advancing-Clinical-Trials-PACT-Reveals-Decentralized-Clinical-Trials-DCTs-Beat-Timeline-Expectations
March 2024
The Rise, Fall, and Eventual Rebound of DCTs | Clinical Leader
This article explores the journey of decentralized clinical trials (DCTs), from their initial surge in popularity and subsequent challenges to their potential resurgence. It provides a critical look at the factors influencing the evolution of DCTs and their role in shaping the future of clinical research. Read more: https://www.clinicalleader.com/doc/the-rise-fall-and-eventual-rebound-of-dcts-0001
June 2023
Optimizing the Process for Adopting DCT Solutions | Applied Clinical Trials
Description: Tufts CSDD Executive Director Ken Getz delves into the complexities of integrating decentralized clinical trial (DCT) solutions, outlining strategies to optimize the adoption process. It examines key challenges, practical approaches, and considerations for organizations transitioning to DCT models in clinical research. Access the full article: https://www.appliedclinicaltrialsonline.com/view/optimizing-the-process-for-adopting-dct-solutions
October 2022
Will DCTs Become the Norm | Clinical Leader
Description: This article explores whether decentralized clinical trials (DCTs) will become the standard approach in clinical research & examines the key factors driving DCT adoption, ongoing challenges, and the potential impact on the future of clinical studies. Read the full column: https://www.clinicalleader.com/doc/will-dcts-become-the-norm-0001
September 2022
Description: This report from Tufts CSDD assesses the financial impact of decentralized and hybrid clinical trials compared to traditional trials. It provides an analysis of how these trial models deliver greater return on investment, examining the cost-effectiveness, efficiency, and overall outcomes. Read more: https://www.medable.com/knowledge-center/long-form-tufts-impact-report-decentralized-hybrid-trials-deliver-greater-roi-than-traditional-trials
Adapting Site Selection for Clinical Trial Decentralization and the Future Landscape | Applied Clinical Trials
Description: This article discusses the shifting landscape of site selection in clinical trials, particularly as decentralization becomes more prevalent. It also examines how traditional site selection strategies are evolving to meet the needs of decentralized and hybrid trial models, and the impact on trial efficiency and outcomes. Read the full article: https://www.appliedclinicaltrialsonline.com/view/adapting-site-selection-for-clinical-trial-decentralization-and-the-future-landscape
July 2022
Decentralized Clinical Trials, Patient Experience and the Role of Supply Chain Management | Fierce Pharma
Description: Decentralized clinical trials (DCTs) are reshaping the way research is conducted, offering patients greater flexibility and convenience. This insightful article dives into the impact DCTs have on patient engagement and the essential role of supply chain management in ensuring success. Discover how these innovations are driving more effective and accessible clinical research: https://www.fiercepharma.com/sponsored/decentralized-clinical-trials-patient-experience-and-role-supply-chain-management
New Data Reveals DCTs Yield Better Clinical Trial ROI | Applied Clinical Trials
Description: A fresh analysis reveals that decentralized clinical trials (DCTs) consistently outperform traditional trials in generating return on investment. This article breaks down the key factors driving these improved outcomes and examines how DCT models are reshaping the future of clinical research. Read the full article: https://www.appliedclinicaltrialsonline.com/view/new-data-reveals-dcts-yield-better-clinical-trial-roi
January 2022
Tufts Links Decentralized Clinical Trials to Shorter Cycle Time, Cost Savings | Outsourcing Pharma
A new study from Tufts CSDD reveals that decentralized clinical trials (DCTs) can lead to substantial time and cost savings compared to traditional trial models. This article delves into the key findings, highlighting the efficiencies DCTs bring and their impact on the clinical research landscape. Read more: https://www.outsourcing-pharma.com/Article/2022/01/28/tufts-links-decentralized-clinical-trials-to-time-cost-savings/
Not Just for a Pandemic: Decentralized Clinical Trials Pay Off Financially, Study Finds | Fierce Biotech
Description: A recent study highlights the financial benefits of decentralized clinical trials (DCTs), showing significant cost savings and efficiency gains compared to traditional approaches. This article explores the key findings and the factors driving these financial advantages in clinical research. Read the article: https://www.fiercebiotech.com/cro/decentralized-studies-offer-financial-benefits-says-new-study